About Michael Howell
Form D filings for Amytrx Therapeutics in 2024 list Michael Howell as director.
Michael Howell first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Howell in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Michael Howell works with at each company, as listed on that company's latest Form D.
Amytrx Therapeutics, Inc. · Form D, Jan 31, 2024
MG
Matthew Gonda
President and CEO, director
LG
Lawrence Greer
Director
SJ
Satish Joshi
Director
DC
Dennis Carlo
Director
RP
Raymond Pirtle
Director